Bulletin Biomérieux Voir en PDF le bulletin du 27 janvier

📢NPArevolut°R📢 Bulletin Biomérieux: Voir en PDF le bulletin du 27 janvier 📢NPA-R #Biomerieux #NPA #Révolution #Bulletin

bioMerieux faces volatility risk ahead of H1 results, RBC maintains hold Investing.com -- bioMerieux may face share price volatility around its upcoming half-year results on September 4, as market expectations for guidance upgrades might not materialize, according to RBC analysts. The bank maintains a Sector Perform rating on the diagnostics company with a price target of €125, noting that while consensus has increased expectations for full-year constant exchange rate (CER) sales growth from 7.4% to 8.4% since April, conditions may not support such upgrades. RBC forecasts second-quarter sales of €973 million, representing 4% year-over-year growth (7% at CER), and first-half core earnings before interest and taxes (cEBIT) of €341 million with a 16.5% margin, in line with consensus estimates. Analysts point to recent weakness in the company’s Microbiology and Immunoassay segments, plus challenging comparisons for respiratory products in the fourth quarter as factors that could prevent bioMerieux from raising its current guidance of "at least" 7% CER growth. Despite these near-term concerns, RBC believes bioMerieux’s mid-term growth drivers remain intact. The company is well-positioned in key markets with opportunities to gain share in new sub-segments, potentially delivering above-market sales growth and double-digit earnings per share growth over the medium term. The diagnostics firm also has significant financial capacity for acquisitions, with RBC estimating approximately €3 billion available this year. Foreign exchange and tariff headwinds are expected to impact margins, with RBC projecting a cumulative FX headwind of about 190 basis points for fiscal years 2024-2025 and a potential tariff headwind of roughly 70 basis points based on updated US-China rates. After strong year-to-date share price performance (+22% versus double-digit declines among peers), bioMerieux now trades at 13.5x 2026 estimated EV/EBITDA and 26.4x P/E, representing premiums of 10% and 38% respectively to selected in-vitro diagnostics peers. RBC considers the current valuation fair, justifying a slight premium to its growth-derived multiple versus peers. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Before you buy stock in BIOX, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is BIOX one of them?

Click Subscribe #bioMerieux #InvestingNews #StockMarket #VolatilityRisk #RBC

NPArevolutionnaires📢 Bulletin Biomérieux: Voir en PDF le bulletin du 5 mai npa-revolutionnaires.org/bulletin-biomerieux-25/ 📢NPA-R #Biomerieux #Bulletin #NPA #Révolutionnaires #Santé

Bulletin Biomérieux Voir en PDF le bulletin du 5 mai

NPArevolutionnaires📢 Bulletin Biomérieux: Voir en PDF le bulletin du 5 mai 📢NPA-R #Biomerieux #Bulletin #NPA #Révolutionnaires #Santé

Fundamental and Technical Analysis of BIM.PA April 2025 Comprehensive Analysis of BIM.PA April 2025, including financial performance, technical indicators, and investment recommendations.

Analysis of BIM.PA April 2025

Comprehensive Analysis of BIM.PA April 2025, including financial performance, technical indicators, and investment recommendations.

tradingtoberich.com/fundamental-...

#biomerieux #biomérieux #trading #tradingstrategy #tradingcards #tradingtips #tradingsignals

Biologiste365 - bioMérieux présente la solution LUMED pour la gestion de l'antimicrobien LUMED est un logiciel d’aide à la décision clinique qui permet de répondre aux enjeux du Bon Usage des Antimicrobiens et de la Prévention du Risque Infectieux à l’hôpital (PRI).

Pour cette #RICAI 2024, #bioMerieux c'était placé sous le signe de la lutte contre l'#antibiorésistance. C'est donc tout naturellement qu'il mettait particulièrement en avant sa solution #LUMED

www.biologiste365.fr/actualites/b...

RAM é tema de webinar organizado pela bioMérieux - CBDL A resistência a antimicrobianos (RAM) é uma das maiores ameaças à saúde global, resultando em infecções mais difíceis de tratar, aumento da mortalidade e maiores custos de saúde. Em 2016, uma publicaç...

RAM é tema de webinar organizado pela bioMérieux:

#CBDL #webinar #biomerieux

cbdl.org.br/ram-e-tema-d...